Boston Scientific stock plunges 9% as Watchman FLX trial results disappoint investors

Boston Scientific stock plunges 9% as Watchman FLX trial results disappoint investors

Sylvia Jordan
Sylvia Jordan
2 Min.
Advertisement for Kelly's Quality Nursery Stock featuring text and images, promoting lowest prices in years.

Boston Scientific stock plunges 9% as Watchman FLX trial results disappoint investors

Boston Scientific has faced a sharp decline in its stock value, dropping nearly 9% in a recent S&P 500 session. The company's shares closed at 62.93 USD (55.60 EUR), marking the lowest point since January 2024. This downturn comes amid broader market struggles and revised analyst expectations for the medical technology firm. The company's market capitalisation has fallen significantly since late March 2024. While US growth figures met investor forecasts, weaker market performance dragged down Boston Scientific's stock. Analysts at Bellevue Medtech noted that, despite overall sector growth, the firm's one-year performance in euros stood at -2.13% compared to MSCI benchmarks.

Raymond James recently downgraded Boston Scientific from *Strong Buy* to *Outperform* and cut its price target from 97 USD to 88 USD. Other research firms, however, still recommend *Buy* or *Outperform*, with targets ranging between 88 USD and 120 USD. The firm also adjusted its revenue projections for 2026 and 2027 downward by 0.5% and 1.5%, respectively. The decline follows mixed trial results for the Watchman FLX device. Data from the CHAMPION-AF trial showed its ischemic stroke rate at 3.2%, compared to 2% for anticoagulants. Despite this, the device met its primary safety goal by reducing non-procedural bleeding complications. Marty Leon, co-principal investigator, called the findings a strong endorsement for wider clinical use. Ken Stein, Boston Scientific's chief medical officer, highlighted that stroke rates in both study arms remained *incredibly low*. The company's electrophysiology and Watchman segments have driven over 50% of its year-over-year revenue growth. Yet, year-to-date, Boston Scientific's stock has fallen 34%, far outpacing the S&P 500's 7.1% decline.

Boston Scientific's stock now sits at its lowest level in months, reflecting both market pressures and adjusted analyst outlooks. The Watchman FLX trial results, while showing safety benefits, also revealed higher stroke rates than anticoagulants. These factors, combined with broader healthcare sector trends, will likely shape the company's performance in the coming quarters.

Neueste Nachrichten